Significance Statement {#s5}
======================

Our study provides evidence for an association between the stress-induced decrease of parvalbumin, a marker of GABAergic interneurons, and the alterations of key players of the oxidative balance. Of particular interest is the observation that chronic treatment with the antipsychotic drug lurasidone is able to normalize the decrease of parvalbumin in parallel with potential antioxidative effects on the NRF2-KEAP1 system as well as on the enzyme NOX2. Our data suggest a close relationship between the alterations of selected GABAergic interneurons and the redox balance that may represent an important mechanism through which lurasidone may ameliorate brain function in stress-related pathologic conditions.

Introduction {#s6}
============

Psychiatric diseases, such as major depression and schizophrenia, are highly disabling disorders characterized by complex etiological mechanisms that lead to functional abnormalities of different neurotransmitters, including monoamines, GABA and glutamate, as well as a dysregulation of inflammation, neuroplasticity, and hormonal signaling ([@CIT0022]; [@CIT0004]; [@CIT0036]; [@CIT0001]). The multifaceted behavioral symptomatology of these disorders involves the perturbation of emotional and cognitive domains of the individual and, among the others, cognitive symptoms have a dramatic impact on the everyday life of the patients ([@CIT0031]). In this context, at the cortical and hippocampal levels, the GABAergic inhibitory tone finely regulates the firing of principal glutamatergic neurons. In more detail, GABAergic interneurons synchronize the firing of principal cells controlling the plasticity of excitatory synaptic inputs through dendritic inhibition, while they inhibit the output with perisomatic inhibition ([@CIT0017]). Among the diverse subtypes of GABAergic interneurons populating the hippocampal formation, parvalbumin (PVB), somatostatin (SST), calbindin (CALB), and neuropeptide-Y (NPY) positive cells represent the most sensitive to stress exposure ([@CIT0014]; [@CIT0012]). Specifically, the highly energized, fast-spiking, PVB positive (PVB+) interneurons play a pivotal role in the processing of complex information. Their contribution in cognitive decline may be fundamental, especially when dysregulation of the energy demand and/or of the oxidative balance may impair their functions ([@CIT0021]). This may occur following exposure to stress, which represents a major environmental condition for mental disorders ([@CIT0039]; [@CIT0008]). Indeed, PVB+ neurons can be part of a critical loop since, while stress may lead to an impairment of this neuronal population ([@CIT0050]), the suppressed function of PVB+ neurons may reduce resilience ([@CIT0037]).

In the present work we used the chronic mild stress (CMS) model ([@CIT0048]) to investigate the detrimental effects of stress on PVB+ cells in rat hippocampus and the potential contribution of a dysregulation in redox mechanisms, which have also been associated with the pathophysiology of several psychiatric disorders ([@CIT0033]; [@CIT0043]; [@CIT0044]). We have previously shown that CMS is able to induce depressive-like behaviors such as anhedonia ([@CIT0040]) as well as cognitive impairment ([@CIT0006]), which are associated with alterations in key molecular players for psychiatric disorders ([@CIT0026]; [@CIT0005]; [@CIT0032]). We also investigated the effect of a chronic treatment with lurasidone in counteracting the CMS-induced alterations in rat hippocampus. Lurasidone is a multi-receptor antipsychotic drug ([@CIT0046]) with demonstrated clinical efficacy for cognitive deficits in schizophrenia ([@CIT0018]) and in bipolar disorder ([@CIT0049]) and depressive symptoms in schizophrenia ([@CIT0034]) and in bipolar depression ([@CIT0024]). We previously demonstrated that chronic lurasidone is able to normalize the stress-induced depressive-like behaviors as well as the neuroplastic and inflammatory alterations observed in stressed rats ([@CIT0026]; [@CIT0040]).

Methods {#s7}
=======

Animals {#s8}
-------

Adult male Wistar rats (Charles River) were brought into the laboratory 1 month before the start of the experiment. Except as described below, the animals were singly housed with food and water freely available and were maintained on a 12-h- light/-dark cycle in a constant temperature (22±2°C) and humidity (50±5%) conditions. All procedures used in this study conform to the rules and principles of the 2010/63/EU Directive and were approved by the Local Bioethical Committee at the Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. All efforts were made to minimize animal suffering and to reduce the number of animals used (n=10 each experimental group).

CMS Procedure and Pharmacological Treatment {#s9}
-------------------------------------------

After a period of adaptation to laboratory and housing conditions, the animals (220±7 g) were subjected to 7 weeks of CMS in parallel with a 5-week-long treatment with lurasidone.

The stress regimen consisted of 2 periods of food or water deprivation, 2 periods of 45° cage tilt, 2 periods of intermittent illumination (lights on and off every 2 h), 2 periods of soiled cage (250 mL water in sawdust bedding), one period of paired housing, 2 periods of low intensity stroboscopic illumination (150 flashes/min), and 3 periods of no stress. All stressors were 10 to 14 hours of duration and were applied individually and continuously, day and night. Control animals were housed in separate rooms and had no contact with the stressed animals. They were deprived of food and water for 14 hours preceding each sucrose test, but otherwise food and water were freely available in the home cage.

Animals were subjected to the stress procedure for 7 weeks. Following the first 2 weeks of stress, both control and stress groups were further divided into matched subgroups, and for the subsequent 5 weeks they received oral administration (by gavage) of vehicle (hydroxy-ethyl-cellulose 1%) or lurasidone (3 mg/kg daily). Our experimental design included 4 groups of animals: unstressed rats that received the vehicle, used as reference control group ("No Stress/Vehicle", n=10); unstressed rats that received the drug (No Stress/Lurasidone, n=10); stressed rats that received the vehicle (Stress/Vehicle, n=10); and stressed rats that received the drug (Stress/Lurasidone, n=10). After 5 weeks, the treatments were terminated, and all control and stressed animals were killed by decapitation 24 hours after the last drug administration. The brains were removed and dissected for prefrontal cortex, dorsal, and ventral hippocampus as fresh tissues. All samples were then rapidly frozen in dry ice/isopentane and stored at −80°C for further molecular analyses.

RNA Preparation and Quantitative Real-Time PCR Analyses {#s10}
-------------------------------------------------------

Total RNA was isolated by single step guanidinium isothiocyanate/phenol extraction using PureZol RNA isolation reagent (Bio-Rad Laboratories S.r.l.) according to the manufacturer's instructions and quantified by spectrophotometric analysis. The samples were processed for PCR as previously described ([@CIT0040]) to measure the mRNA expression of *Pvb*, *Sst*, *Calb*, *Npy*, NADPH oxygenase 2 (*Nox2*), nuclear factor (erythroid-derived 2)-like 2 (*Nrf2*), sulfiredoxin (*Srxn*), hemeoxigenase-1 (*Ho-1*), NAD(P)H dehydrogenase \[quinone\]1 (*Nqo1*), and catalase (*Cat*). Primer and probe sequences are listed in [Table 1](#T1){ref-type="table"}.

###### 

Sequences of Forward and Reverse Primers and Probes used in qRT-PCR Analysis

  Gene              Forward Primer            Reverse Primer            Probe
  ----------------- ------------------------- ------------------------- ------------------------------
  ***Pvalb\****     CTGGACAAAGACAAAAGTGGC     GACAAGTCTCTGGCATCTGAG     CCTTCAGAATGGACCCCAGCTCA
  ***Sst\****       ACTCCGTCAGTTTCTGCAG       CAGGGCATCGTTCTCTGTC       AGTTCCTGTTTCCCGGTGGCA
  ***Calb\****      AGAACTTGATCCAGGAGCTTC     CTTCGGTGGGTAAGACATGG      TGGGCAGAGAGATGATGGGAAAATAGGA
  ***Npy\****       GACAGAGATATGGCAAGAGATCC   CTAGGAAAAGTCAGGAGAGCAAG   CCCCAGAACAAGGCTTGAAGACCC
  ***Nrf2\*\****    Rn00582415_m1                                       
  ***Keap1\*\****   Rn01448220_m1                                       
  ***Nox2\*\****    Rn00675098_m1                                       
  ***Srnx\*\****    Rn04337926_g1                                       
  ***Ho-1\*\****    Rn00561387_m1                                       
  ***Nqo1\*\****    Rn00566528_m1                                       
  ***Cat\*\****     Rn00560930_m1                                       
  ***ß Actin\****   CACTTTCTACAATGAGCTGCG     CTGGATGGCTACGTACATGG      TCTGGGTCATCTTTTCACGGTTGGC

Purchased from Eurofins MWG Operon (Germany)\* and Applied Biosystem (Italy)\*\*.

Specifically, RNA aliquots of each sample were treated with DNase to avoid DNA contamination and then analyzed by TaqMan qRT-PCR instrument (CFX384 real-time system, Bio-Rad Laboratories) using the iScript one-step RT-PCR kit for probes (Bio-Rad Laboratories). The samples were run in 384-well formats in triplicate as multiplexed reactions with a normalizing internal control (β-Actin).

Thermal cycling was initiated with an incubation at 50°C for 10 minutes (RNA retro-transcription) and then at 95°C for 5 minutes (TaqMan polymerase activation). After this initial step, 39 cycles of PCR were performed. Each PCR cycle consisted of heating the samples at 95°C for 10 seconds to enable the melting process and then for 30 seconds at 60°C for the annealing and extension reaction. A comparative cycle threshold (Ct) method was used to calculate the relative target gene expression vs the control group. Specifically, fold change for each target gene relative to β-actin was determined by the 2-∆(∆CT) method, where ∆CT=CT(target)-CT(β-actin); ∆(∆CT)=∆CT(exp. group)-∆CT(control group); CT is the threshold cycle. For graphical clarity, the obtained data were then expressed as percentage vs control group, which has been set at 100%.

Protein Extraction and Western-Blot Analyses {#s11}
--------------------------------------------

Brain samples were manually homogenized using a glass-glass potter in a pH 7.4 cold buffer (containing 0.32 M sucrose, 0.1 mM EGTA, 1 mM HEPES solution, and 0.1 mM phenylmethylsulfonyl fluoride in presence of a complete set of proteases \[Roche\] and phosphatase \[Sigma-Aldrich\] inhibitors) and then sonicated for 10 seconds at a maximum power of 10% to 15% (Bandelin Sonoplus). The homogenate was clarified (1000 g; 10 minutes), obtaining a pellet (P1) enriched in nuclear components, which was resuspended in a buffer (1 mM HEPES, 0.1mM dithiothreitol, 0.1 mM EGTA) supplemented with protease and phosphatase inhibitors. The supernatant (S1) was then centrifuged (13000g; 15 minutes) to obtain a clarified fraction of cytosolic proteins (S2). The pellet (P2), corresponding to the crude membrane fraction, was resuspended in the same buffer used for the nuclear fraction. Total protein content was measured according to the Bradford Protein Assay procedure (Bio-Rad Laboratories), using bovine serum albumin as calibration standard.

Protein analyses were performed in the whole homogenate (for PVB), in the cytosolic fraction (for NRF2 and KEAP1), and in the crude membrane fraction (for NOX2). Equal amounts of protein (10 μg for the homogenate, 30 μg for the S2, and 15 μg for the P2) were run under reducing conditions on polyacrylamide gels and then electrophoretically transferred onto polyvinylidene fluoride or nitrocellulose membranes. Unspecific binding sites were blocked with 10% nonfat dry milk; then the membranes were incubated overnight with the primary antibodies and for 1 hour at room temperature with a peroxidase-conjugated anti-rabbit or anti-mouse IgG ([Table 2](#T2){ref-type="table"}). Immunocomplexes were visualized by chemiluminescence using the ECL Star (Euroclone), ECL Plus (Euroclone), or ECL Clarity (Bio-Rad Laboratories). Results were standardized using β-actin as the internal control, which was detected by evaluating the band density at 43 kDa. Protein levels were calculated by measuring the optical density of the immunocomplexes using chemiluminescence (Chemidoc MP Imaging System, Bio-Rad Laboratories). To ensure that autoradiographic bands would be in the linear range of intensity, different exposure times were used.

###### 

Primary and Secondary Antibodies Used in Western-Blot Analyses

  --------------------------------------------------------------------------------------------------------
  Primary Antibody                 Primary Antibody Condition      Secondary Antibody Condition
  -------------------------------- ------------------------------- ---------------------------------------
  PVB, 10 kDa (Abcam)              1:2500 in 5% nonfat dry milk\   1:2500, anti-rabbit (Cell Signaling)\
                                   4°C o/n                         5% nonfat dry milk, 1h, RT

  NRF2, 110 kDa (R&D System)       1:500 in 5% BSA\                1:500, anti-mouse (Sigma-Aldrich)\
                                   4°C o/2n                        5% BSA, 1h, RT

  KEAP1, 66 kDa (R&D System)       1:250 3% nonfat dry milk\       1:500, anti-mouse (Sigma-Aldrich)\
                                   4°C o/n                         5% nonfat dry milk, 1h, RT

  NOX2, 58 kDa (BD)                1:500 3% nonfat dry milk\       1:500, anti-mouse (Sigma-Aldrich)\
                                   4°C o/n                         3% nonfat dry milk, 1h, RT

  β-ACTIN 43 kDa (Sigma-Aldrich)   1:2000 in 3% nonfat dry milk\   1:20000, anti-mouse (Sigma-Aldrich)\
                                   1h, RT                          3% nonfat dry milk, 1h, RT
  --------------------------------------------------------------------------------------------------------

Abbreviations: BSA, bovine serum albumin; o/n, overnight; o/2n, over 2 nights; RT, room temperature.

Statistical Analyses {#s12}
--------------------

The effects of drug treatment (lurasidone) and chronic stress exposure on the mRNA or protein levels of our molecular targets were analyzed by 2-way ANOVA followed, when appropriate, by Fisher's Least Significant Difference (LSD) posthoc comparisons. In addition, to evaluate the association between the modulation of the NRF2-KEAP1 system and the protein levels of PVB, Pearson product-moment correlation coefficients (r) were calculated between NRF2 or KEAP1 protein and PVB levels. Significance for all tests was assumed for *P\<*.05. Data are presented as means±SEM. SPSS (Release 24.0.0.0) was used to perform the statistical analyses.

RESULTS {#s13}
=======

Analysis of the mRNA Levels for Different Subtypes of GABAergic Interneurons in Rats Exposed to CMS and Treated with Lurasidone {#s14}
-------------------------------------------------------------------------------------------------------------------------------

We first investigated the mRNA levels of the GABAergic markers *Pvb*, *Sst*, *Npy*, and *Calb* in the dorsal (D-HIP) and ventral (V-HIP) hippocampus of animals exposed to CMS and treated, or not, with the antipsychotic drug lurasidone.

The analysis of *Pvb* gene expression in the D-HIP showed a significant interaction between CMS and lurasidone treatment (F~3,32~=11.755, *P\<*.01). Indeed, stress exposure led to a significant decrease of *Pvb* mRNA levels (-18% vs No Stress/Vehicle, *P\<*.05; [Figure 1A](#F1){ref-type="fig"}), which was normalized by pharmacological intervention (+19% vs Stress/Vehicle, *P\<*.05; [Figure 1A](#F1){ref-type="fig"}). Of note, lurasidone administration per se produced a significant decrease of *Pvb* compared with control rats (-16% vs No Stress/Vehicle, *P\<*.05; [Figure 1A](#F1){ref-type="fig"}). These changes appeared to be specific for the dorsal part of the hippocampus, since no significant changes were found in the ventral counterpart ([Figure 1E](#F1){ref-type="fig"}).

![Gene expression analysis of interneuron markers parvalbumin (*Pvb*), somatostatin (*Sst*), neuropeptide y (*Npy*), and calbindin (*Calb*) in the dorsal and ventral hippocampus of rats exposed to chronic mild stress (CMS): modulation by lurasidone treatment. The mRNA levels of *Pvb*, *Sst*, *Npy*, and *Calb* were measured in the dorsal (A--D) and ventral (E--H) hippocampus of rats exposed to CMS in combination with chronic treatment with vehicle or lurasidone. The data, expressed as a percentage of unstressed rats treated with vehicle (No Stress/Vehicle set at 100%), are the mean +/- SEM of at least 7 independent determinations. \**P\<*.05, \*\**P\<*.01, \*\*\**P\<*.001 vs No Stress/Vehicle; \#\#*P\<*.01, \#\#\#*P\<*.001 vs Stress/Vehicle (2-way ANOVA with PLSD).](pyy04601){#F1}

When investigating *Sst* expression in the D-HIP, we found a significant effect of CMS exposure (F~3,35~=10.023, *P\<*.01) as well as of pharmacological treatment (F~3,35~=33.850, *P\<*.001). As shown in [Figure 1B](#F1){ref-type="fig"}, *Sst* levels were increased in rats subjected to CMS (+58% vs No Stress/Vehicle, *P\<*.01; [Figure 1B](#F1){ref-type="fig"}), whereas chronic lurasidone treatment upregulated *Sst* expression in nonstressed rats (+98% vs No Stress/Vehicle, *P\<*.001; [Figure 1B](#F1){ref-type="fig"}) as well as in stressed animals (+75% vs Stress/Vehicle, *P\<*.001; [Figure 1B](#F1){ref-type="fig"}). In the V-HIP, we found a main effect of CMS on *Sst* mRNA levels (F~3,36~=6.687, *P\<*.05) that led to a significant decrease of this marker in stressed rats compared with control animals (-21% vs No Stress/Vehicle, *P\<*.05; [Figure 1F](#F1){ref-type="fig"}), an effect that was not modulated by the pharmacological treatment.

Conversely, the expression of the other GABAergic markers, namely *Npy* ([Figure 1C](#F1){ref-type="fig"}, [G](#F1){ref-type="fig"}) and *Calb* ([Figure 1D](#F1){ref-type="fig"}, [H](#F1){ref-type="fig"}), was not significantly modulated in the dorsal or ventral portion of the hippocampus following CMS exposure or lurasidone treatment, providing further support to the selectivity exerted by CMS exposure on specific subpopulations of GABAergic neurons.

No significant changes were observed in the prefrontal cortex of stressed rats treated or not with chronic pharmacological treatment ([Table 3](#T3){ref-type="table"}).

###### 

Gene Expression Analysis of Interneuron Markers *Pvb*, *Sst*, *Calb*, and *Npy* in the Prefrontal Cortex of Rats Exposed to CMS

               No Stress   Lurasidone   Stress   Lurasidone/Stress
  ------------ ----------- ------------ -------- -------------------
  ***Pvb***    100±5       92±6         95±5     90±3
  ***Sst***    100±6       117±8        103±5    110±8
  ***Calb***   100±5       99±8         97±4     99±3
  ***Npy***    100±4       96±3         96±6     97±4

The mRNA levels of parvalbumin (*Pvb*), somatostatin (*Sst*) neuropeptide y (*Npy*) and calbindin (*Calb*) were measured in the prefrontal cortex of rats exposed to CMS, in combination with chronic treatment with vehicle or lurasidone. The data expressed as a percentage of unstressed rats treated with vehicle (No Stress/Vehicle set at 100%) are the mean +/- SEM of at least 7 independent determinations.

Analysis of PVB Protein Levels in the Hippocampus of Animals Exposed to CMS and Treated with Lurasidone {#s15}
-------------------------------------------------------------------------------------------------------

Based on the gene expression analyses of different interneuron markers, we decided to focus on PVB and analyzed its protein levels in D-HIP and V-HIP of rats exposed to CMS, with or without lurasidone treatment. Within D-HIP, as depicted in [Figure 2A](#F2){ref-type="fig"}, we found a main effect of CMS exposure (F~3,35~=12.164, *P\<*.001) and lurasidone treatment (F~3,35~=19.860, *P\<*.001) as well as a significant CMS x treatment interaction (F~3,35~=7.710, *P\<*.01). Indeed, the levels of PVB were markedly reduced in rats exposed to CMS and treated with vehicle (-58% vs No Stress/Vehicle, *P\<*.001; [Figure 2A](#F2){ref-type="fig"}), whereas chronic lurasidone treatment was able to normalize the CMS-induced changes of PVB levels (+67% vs Stress/Vehicle, *P\<*.001; [Figure 2A](#F2){ref-type="fig"}).

![Protein expression of parvalbumin (PVB) in the hippocampus of rats exposed to chronic mild stress (CMS): modulation by lurasidone treatment. The protein levels of PVB were measured in the dorsal (A) and ventral (B) hippocampus of rats exposed to CMS in combination with chronic treatment with vehicle or lurasidone. The data, expressed as a percentage of unstressed rats treated with vehicle (No Stress/Vehicle, set at 100%), are the mean +/- SEM of at least 6 independent determinations. Representative western blot bands of PVB are shown under the respective graphs. \*\*\**P\<*.001 vs No Stress/Vehicle; \#\#\#*P\<*.001 vs Stress/Vehicle (2-way ANOVA with PLSD).](pyy04602){#F2}

In line with the gene expression data, these alterations show anatomical selectivity. Indeed, within the V-HIP ([Figure 2B](#F2){ref-type="fig"}), despite a main effect of CMS exposure (F~3,35~=9.486, *P\<*.01), we only found a trend toward a decrease of PVB levels in stressed animals (-16% vs No Stress/Vehicle *P=*.054), which was not influenced by the pharmacological treatment.

Analysis of NADPH Oxidase-2 Gene and Protein Expression in the Dorsal Hippocampus of Animals Exposed to CMS and Treated with Lurasidone {#s16}
---------------------------------------------------------------------------------------------------------------------------------------

PVB neurons show a sustained firing activity that requires a high demand of energy, which may expose them to an increased susceptibility toward the detrimental effects of oxidative stress. On these bases, we investigated if the effects of CMS exposure in D-HIP could be associated with alterations of molecules involved in the complex machinery regulating the oxidative balance in the brain. We analyzed the gene expression of *Nox2*, an enzyme responsible for the production of reactive oxygen species by activated macrophages, including microglia. The analysis of *Nox2* mRNA levels in D-HIP revealed a significant interaction between stress and lurasidone administration (F~37,3~=4.521, *P\<*.05). Indeed, the direct comparisons between groups showed that *Nox2* gene expression increased in rats exposed to CMS (+33% vs No Stress/Vehicle, *P\<*.05; [Figure 3A](#F3){ref-type="fig"}), an effect that was not present in CMS rats chronically treated with lurasidone. We then investigated the protein levels of gp91^PHOX^, the main membrane-bound subunit of the enzyme. As depicted in [Figure 3B](#F3){ref-type="fig"}, stress exposure had a main effect on NOX2 protein levels (F~33,3~=7,121 *P\<*.05), since CMS rats showed an increase of NOX2 compared with control animals (+98% vs No Stress/Vehicle, *P\<*.01; [Figure 3B](#F3){ref-type="fig"}), an effect that was attenuated by chronic lurasidone administration.

![Gene expression and protein analyses of NADH oxidase-2 (NOX2) in the dorsal hippocampus of rats exposed to chronic mild stress (CMS): modulation by lurasidone treatment. The mRNA (A) and the protein levels (B) of NOX2 were measured in the dorsal hippocampus of rats exposed to CMS in combination with chronic treatment with vehicle or lurasidone. The data, expressed as a percentage of unstressed rats treated with vehicle (No Stress/Vehicle, set at 100%), are the mean +/- SEM of at least 8 independent determinations. Representative western-blot bands of NOX2 are shown under the respective graph. \**P\<*.05, \*\**P\<*.01 vs No Stress/Vehicle (2-way ANOVA with PLSD).](pyy04603){#F3}

Analysis of the NRF2-KEAP1 Antioxidant System in the Dorsal Hippocampus of Animals Exposed to CMS and Treated with Lurasidone {#s17}
-----------------------------------------------------------------------------------------------------------------------------

The NRF2 and the Kelch-like ECH-associated protein 1 (KEAP1) have a pivotal role in the control of the cellular antioxidant response. Indeed, upon nuclear translocation NRF2 binds to its consensus sequences (the so-called antioxidant responsive elements) to promote the transcription of several enzymes involved in the cellular mechanisms of detoxification. The transcription factor interacts in the cytosol with KEAP1, a chaperon protein that prevents its translocation into the nucleus, thus inhibiting its transcriptional antioxidant activity.

When considering the expression of the transcription factor *Nrf2*, we found a statistically significant interaction between CMS and lurasidone treatment (F~3,36~=11.616, *P\<*.01). Indeed, as shown in [Figure 4A](#F4){ref-type="fig"}, while CMS exposure produced a slight, non-significant decrease of the transcription factor (-11% vs No Stress/Vehicle, *P\>*0.05), lurasidone was able to increase its mRNA levels only when administered to CMS animals (+24% vs Stress/Vehicle, *P\<*.01). Based on gene expression analyses, we decided to deepen our investigation by assessing the protein levels of NRF2 as well as of its inhibitor KEAP1 in the D-HIP.

The analysis of the protein levels of NRF2 revealed a significant stress\*lurasidone interaction (F~3,32~=4.195, *P\<*.05). Indeed, as shown in [Figure 4B](#F4){ref-type="fig"}, the protein levels of NRF2 were decreased by CMS (-40% vs No Stress/Vehicle, *P\<*.05), an effect that was, at least in part, restored by lurasidone treatment considering that the levels of NRF2 protein in Stress/Lurasidone group did not differ from sham rats.

![Analysis of nuclear factor-E2-related factor-2 (NRF2)-kelch like ECH associated protein-1 (KEAP1) expression in the dorsal hippocampus of rats exposed to chronic mild stress: modulation by lurasidone treatment. The mRNA (A) and protein levels (B) of NRF2 and the protein levels of the chaperon protein KEAP1 (C) were measured in the cytosolic fraction of the dorsal hippocampus of rats exposed to chronic mild stress (CMS) in combination with chronic treatment with vehicle or lurasidone. The data, expressed as a percentage of unstressed rats treated with vehicle (No Stress/Vehicle, set at 100%), are the mean +/- SEM of at least 7 independent determinations. Representative western-blot bands of NRF2 and KEAP1 are shown under the respective graphs. \**P\<*.05, \*\**P\<*.01 vs No Stress/Vehicle; \#\#*P\<*.01 vs Stress/Vehicle (2-way ANOVA with PLSD).](pyy04604){#F4}

Interestingly, KEAP1 levels were strongly modulated by chronic lurasidone treatment (F~3,30~=15.226, *P\<*.001). Indeed, although CMS exposure did not affect KEAP1 levels, chronic lurasidone administration significantly reduced its protein levels in sham (-48% vs No Stress/Vehicle, *P\<*.01; [Figure 4C](#F4){ref-type="fig"}) as well as in CMS rats (-55% vs Stress/Vehicle, *P\<*.05; [Figure 4C](#F4){ref-type="fig"}).

Pearson Correlation Analysis between NRF2/KEAP1 Protein Levels and PVB in the Dorsal Hippocampus of Animals Exposed to CMS and Treated with Lurasidone {#s18}
------------------------------------------------------------------------------------------------------------------------------------------------------

Next, to establish a potential relationship between the effects of stress exposure and pharmacological treatment on PVB expression with the levels of NRF2/KEAP1 antioxidant system, we performed a Pearson product-moment correlation coefficient analysis between the protein levels of NRF2 or KEAP1 and the protein levels of PVB in the D-HIP. As presented in [Figure 5](#F5){ref-type="fig"}, NRF2 showed a significant positive correlation with the GABAergic marker (r=0.414, *P\<*.05; [Figure 5A](#F5){ref-type="fig"}), while a negative correlation was observed between the chaperone protein KEAP1 and PVB (r=-0.501, *P\<*.01; [Figure 5B](#F5){ref-type="fig"}).

![Pearson correlation analysis between nuclear factor-E2-related factor-2 (NRF2) or kelch like ECH associated protein-1 (KEAP1) and parvalbumin (PVB) protein levels in the dorsal hippocampus. The Pearson moment-product correlation (r) between NRF2 (A), KEAP1 (B), and PVB protein levels were measured in the dorsal hippocampus of rats exposed to chronic mild stress (CMS) in combination with chronic treatment with vehicle or lurasidone. The statistical significance was assumed with *P\<*.05.](pyy04605){#F5}

Analysis of the Transcriptional Effects of NRF2 in the Dorsal Hippocampus of Animals Exposed to CMS and Treated with Lurasidone {#s19}
-------------------------------------------------------------------------------------------------------------------------------

Based on the changes in the functional interplay between NRF2 and KEAP1 after CMS exposure and/or lurasidone treatment, we decided to investigate the expression of some genes downstream from the transcriptional activity of NRF2, namely the enzymes *Srnx1*, *Ho-1*, *Nqo1*, and *Cat*.

As depicted in [Figure 6](#F6){ref-type="fig"}, the expression of *Srxn1* (A) and *Ho-1* (B) were not modulated by CMS exposure or chronic lurasidone treatment. However, we found that the mRNA levels of *Nqo1* showed a significant stress x treatment interaction (F~3,37~=7.806, *P\<*.01). Indeed, chronic treatment with lurasidone was able to upregulate its expression, only when administered to CMS animals (+23% vs Stress/Vehicle, *P\<*.01; [Figure 6C](#F6){ref-type="fig"}). Moreover, we found a significant main effect of lurasidone treatment (F~3,38~=6.334, *P\<*.05) on *Cat* gene expression. Specifically, the pharmacological treatment increased the levels of the enzyme, but only when it was administered to sham animals (+21% vs No Stress/Vehicle, *P\<*.05; [Figure 6D](#F6){ref-type="fig"}).

![Analysis of nuclear factor-E2-related factor-2 (NRF2)-induced transcriptional response in the dorsal hippocampus of rats exposed to chronic mild stress (CMS): modulation by lurasidone treatment. The mRNA levels of Sufiredoxin (*Srxn1*, A), Heme oxigenase-1 (*Ho-1*, B), NAD(P)H dehydrogenase \[quinone\]-1 (*Nqo1*, C), and Catalase (*Cat*, D) were measured in the dorsal hippocampus of rats exposed to CMS in combination with chronic treatment with vehicle or lurasidone. The data, expressed as a percentage of unstressed rats treated with vehicle (No Stress/Vehicle, set at 100%), are the mean +/- SEM of at least 8 independent determinations. \**P\<*.01 vs No Stress/Vehicle; \#\#*P\<*.01 vs Stress/Vehicle (2-way ANOVA with PLSD).](pyy04606){#F6}

Discussion {#s20}
==========

In recent years the interest in GABAergic interneurons has gained much attention due to their key role in functions that are altered in different psychiatric disorders, including major depression and schizophrenia ([@CIT0028]; [@CIT0036]). Within this context, our data point out that the restorative effect of pharmacological treatment on PVB expression may be mediated by the drug-mediated regulation of the oxidative balance within the brain.

Most PVB-expressing cells are present in the central nervous system as interneurons, particularly within selected brain structures, including cerebral cortex, hippocampus, cerebellum, and spinal cord ([@CIT0050]). In the hippocampus, a critical brain area involved in the control of emotional states, stress response, and cognitive function ([@CIT0013]), PVB+ cells are mostly fast-spiking GABAergic interneurons that control the circuitry activity of pyramidal cells through their inhibitory activity. The reduction of PVB expression found in the D-HIP of CMS exposed rats is in line with the detrimental effects of stress or other adverse manipulations on the GABAergic system reported in other preclinical studies. For example, Czeh and collaborators have shown that 5 weeks of psychosocial stress were able to impair PVB expression in specific subregions of treeshrew hippocampus ([@CIT0011]). Similar results were obtained with other stress paradigms in rats, such as chronic immobilization ([@CIT0020]) and social isolation ([@CIT0014]). Interestingly, in our experimental setting, the D-HIP appears to be more vulnerable to the impact of CMS, an effect that is in line with the results of Czeh and co-workers ([@CIT0012]). Considering that functional alterations of this hippocampal subregion have a major role in cognitive dysfunctions, we hypothesize that reduced PVB expression may contribute to the impaired cognitive function we have recently shown in rats exposed to the CMS paradigm ([@CIT0006]). It is likely that the expression of PVB may be due to a decrease of protein expression instead of to cell loss. Indeed, as demonstrated by others, chronic stress exposure does not increase caspase-3 expression in GABAergic interneurons ([@CIT0014]). Interestingly, we found a strong induction of SST expression in the D-HIP following stress exposure. In both hippocampus and neocortex, PVB+ interneurons target the soma and the perisomatic dendrites of pyramidal neurons, controlling the output signaling of principal excitatory neurons. In parallel, SST interneurons generally target the more distal dendrites, gating the excitatory signals ([@CIT0019]). Moreover, the activity of PVB and SST interneurons is strictly interconnected as part of complex inhibitory microcircuits involved in the control of behavior and learning ([@CIT0007]). Considering that SST decrease has been causally related to anxiety/depression-like behaviors ([@CIT0023]), our result may seem counterintuitive. However, the increased expression of SST may represent a compensatory mechanism to limit the impaired somato-dendritic inhibition of pyramidal neurons after CMS-induced PVB loss. In parallel, the increase of SST observed after lurasidone treatment may be related to a specific mechanism induced by the drug, which is independent from the model analyzed. Indeed, we have previously shown a similar effect in serotonin transporter knockout rats treated with lurasidone ([@CIT0025]). In this sense, further functional studies are needed to better clarify the impact of pharmacological treatment with psychotropic drugs on these interneuron populations.

The opposite effects of CMS on these two markers may also explain why the protein levels of the glutamic acid decarboxylase 67 were not modulated by stress exposure in the D-HIP (data not shown). Indeed, we may speculate that in our experimental setting this enzyme is differentially modulated in the diverse interneuron subpopulations.

While the precise detrimental mechanisms triggered by stress exposure on PVB interneurons are not well clarified, the selective vulnerability of PVB+ interneurons to chronic stress may be due to their peculiar fast spiking activity. The firing of PVB interneurons requires a high amount of energy, and the increased metabolic activity under certain conditions, such as stress, may expose PVB neurons to potentially toxic effects of reactive oxygen and nitrogen species, which alter the redox balance of the cell ([@CIT0021]).

In this respect, the NOX family represents a very important group of enzymes that, especially in the injured nervous system, is a major source of reactive oxygen species ([@CIT0010]). The upregulation of NOX2 expression after stress suggests an increase of the prooxidative activity in rats exposed to CMS. Increased levels of NOX2 have also been observed in brain areas of animals exposed to prolonged social isolation from weaning ([@CIT0042]) as well as in a model of posttraumatic stress disorder, where NOX2 upregulation was paralleled by a decrease of PVB expression ([@CIT0045]). Considering that NOX2 has been reported as the primary phagocytic oxidase ([@CIT0002]), its altered expression may be associated with the increased activity of microglial cells under stressful conditions. In parallel, the production of prooxidative agents from NOX2 induces the activation of microglia, triggering a detrimental inflammatory loop, potentially harmful for neurons ([@CIT0047]). This hypothesis is supported by previous data from our laboratory showing increased expression of hippocampal CD11b, a marker of microglia activation, in animals exposed to 7 weeks of CMS ([@CIT0040]). Although in the present study we measured the levels of gp190^PHOX^, the principal membrane subunit of NOX2 enzyme, without evaluating other subunits of the enzymatic complex, we believe that the expression of the fundamental enzymatic subunit may reflect an increased response of the prooxidative system within the hippocampus. The detrimental effects of oxidative stress on PVB expression observed in response to CMS may also be the result of a glucocorticoid receptor (GR)-dependent extragenomic mechanism, which may affect the firing activity of these interneurons. Indeed, it has been proposed that the activation of membrane bound GR may induce the production of nitric oxide (NO), a small neurotransmitter responsible of the activation of PVB positive interneurons ([@CIT0020]). The sustained activation of GR during chronic stressful condition may decrease PVB expression by sensitizing interneuron activation and, possibly, through a toxic effect due to NO release. Indeed, NO may be converted in different reactive nitrogen species, thus leading to oxidative damage of proteins, lipids, and DNA that are able to alter neuronal homeostasis ([@CIT0033]). We also showed that prolonged stress exposure alters the NRF2-KEAP-antioxidant responsive element system, a master regulator of the antioxidative response ([@CIT0041]), with a decrease of NRF2 expression that may impair the activation of antioxidant mechanisms. Our results are in line with previous studies showing the negative effects of stress on NRF2. For example, a decreased expression of NRF2, with a parallel increase of oxidative stress, was found in social defeat-vulnerable animals exposed to chronic stress ([@CIT0003]) as well as in rats exposed to 4 weeks of chronic stress ([@CIT0035]).

Chronic treatment with lurasidone, an antipsychotic drug approved for the treatment of schizophrenia and bipolar depression, was able to normalize CMS-induced decrease of PVB expression in D-HIP. In this sense, other studies support the idea that antipsychotic drugs, such as clozapine ([@CIT0015]) and risperidone ([@CIT0038]), may regulate the function of GABAergic interneurons through the modulation of specific markers. While these drugs share high affinity for 5-HT7 receptors, it is difficult to ascertain if this is the unique mechanism through which these agents modulate GABAergic function, considering the vast heterogeneity in their receptor profiles. Indeed, we believe that the observed effects represent adaptive mechanisms following prolonged drug administration regulating complex neuronal circuits that will eventually lead to changes in selective GABAergic subtypes. Lastly, the effect of lurasidone closely resembles what we have recently observed in the hippocampus of adult mice exposed to prenatal immune challenge ([@CIT0027]).

Due to the peculiar receptor profile of lurasidone, it is difficult to enlighten a molecular mechanism responsible for the effects of the pharmacological treatment on GABAergic interneurons. Our results, however, suggest that the ability of lurasidone to modulate the oxidative stress balance may be part of its restorative effect. Indeed, chronic lurasidone treatment was able to induce the gene expression of NRF2 only in stressed animals, suggesting an antioxidative effect of the pharmacological treatment only under adverse conditions. The positive effect of lurasidone was also found at the translational level, since the CMS-induced decrease of NRF2 was partially normalized in animals treated with the antipsychotic drug. Interestingly lurasidone is also able to regulate KEAP1, a chaperone protein that segregates NRF2 into the cytosol and promotes its proteasome-mediated degradation ([@CIT0041]). Indeed, while KEAP1 protein levels in the cytosolic fraction were not altered by CMS exposure, we found that lurasidone treatment was able to reduce its levels, suggesting that the drug not only increases the expression of NRF2 but may also promote its activity through a negative modulation of KEAP1.

Our results suggest that, in addition to synaptic and neuroplastic mechanisms ([@CIT0046]; [@CIT0026]), lurasidone is able to modulate the brain oxidative balance, which may contribute to its therapeutic effects and eventually enhance neuronal resiliency. Interestingly, similar mechanisms have also been described for other psychotropic drugs, including antidepressants ([@CIT0030]; [@CIT0035]) and antipsychotics ([@CIT0029]). It is interesting to note that the modulation of NRF2 and KEAP1 showed a significant Pearson correlation (positive and negative, respectively) with PVB protein levels, providing further support to the notion that the alterations of the GABAergic system following CMS exposure may be causally linked to a dysregulation of the oxidative balance in the D-HIP. In addition, the pharmacological treatment with lurasidone was able to induce the expression of key antioxidant enzymes related to NRF2 transcriptional activity. The specific increased levels of *Nqo1* and *Catalase* support the idea of an antioxidative activity of the drug. This is in line with previously published data showing that, although stress exposure did not impair the transcription of antioxidant enzyme, the administration of an atypical antipsychotic increased antioxidant response in stressed animals ([@CIT0029]).

In summary, the susceptibility of PVB neurons to stress may represent a key mechanism contributing to functional and structural deterioration in specific brain regions, such as the D-HIP, associated with psychiatric illness. The ability to counteract PVB alterations, for example with antioxidants/redox regulators ([@CIT0044]), or to promote the activity of PVB neurons ([@CIT0009]) may represent a novel and important strategy to promote resilience. In this respect, our data provide new insights on the mechanism of action of lurasidone in the context of stress-related hippocampal dysfunction, suggesting that its pharmacological profile, which can improve neuronal/synaptic plasticity in hippocampus and cortex through both protective (antioxidant) and functional (BDNF) ([@CIT0026]) mechanisms, should support clinical efficacy reported in schizophrenia and bipolar disorder.
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